Fig. 7: Design of EBOVAC 1 (EBL 1001, 1003, 1004, and 3001) and EBOVAC 2 (EBL 2001 and 2002) trials for participants receiving Ad26, MVA D57 as vaccine regimen.
Immunogenicity measurements provide the concentration of IgG-binding antibodies against Ebola, as measured by ELISA (ELISA units/mL).
